이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발 또는 내화성 T 세포 비호 지킨 림프종을 가진 참가자에서 KK2223에 대한 최초의 인간 연구

2026년 9월 29일 업데이트: Kyowa Kirin, Inc.

1 상, 다기관, 오픈 라벨, 비 랜덤 화, 복용량 에스컬레이션 및 재발 성 T- 세포 비 호 지킨 림프종을 가진 참가자의 KK2223의 백필 연구

The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)

연구 유형

중재적

등록 (추정된)

72

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • California
      • Duarte, California, 미국, 91010
        • 아직 모집하지 않음
        • City of Hope
        • 수석 연구원:
          • Christina Poh
        • 연락하다:
          • Christina Poh
          • 전화번호: 916-734-7131
          • 이메일: cpoh@coh.org
      • Orange, California, 미국, 92868
        • 아직 모집하지 않음
        • University of California, Irvine Medical Center - Hematology/Oncology
        • 연락하다:
        • 수석 연구원:
          • Lauren Pinter Brown
      • Stanford, California, 미국, 94305
        • 모병
        • Stanford University School of Medicine
        • 수석 연구원:
          • Youn Kim
        • 연락하다:
    • Florida
      • Tampa, Florida, 미국, 33612
        • 아직 모집하지 않음
        • Moffit Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Yumeng Zhang
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • 아직 모집하지 않음
        • Emory University Medical Center
        • 수석 연구원:
          • Pamela Allen
        • 연락하다:
    • Iowa
      • Iowa City, Iowa, 미국, 52242
        • 아직 모집하지 않음
        • University of Iowa Health
        • 수석 연구원:
          • Eric Mou
        • 연락하다:
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • 아직 모집하지 않음
        • Beth Israel Deaconess Medical Center - Research
        • 연락하다:
        • 수석 연구원:
          • Salvia Jain
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • 모병
        • Washington University School of Medicine - Oncology Hospital - Public
        • 수석 연구원:
          • Neha Mehta Shah
        • 연락하다:
    • New Jersey
      • Hackensack, New Jersey, 미국, 07601-2105
        • 아직 모집하지 않음
        • Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
        • 수석 연구원:
          • Tatyana Feldman
        • 연락하다:
    • New York
      • New York, New York, 미국, 10021-6007
        • 모병
        • Memorial Sloan Kettering Cancer Center
        • 수석 연구원:
          • Jasmine Zain
        • 연락하다:
    • Ohio
      • Cleveland, Ohio, 미국, 44106
        • 아직 모집하지 않음
        • University Hospitals Cleveland Medical Center
        • 연락하다:
        • 수석 연구원:
          • Kevin Cooper
    • Oregon
      • Portland, Oregon, 미국, 97239
        • 아직 모집하지 않음
        • Oregon Health & Science University
        • 연락하다:
        • 수석 연구원:
          • Craig Okada
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • 아직 모집하지 않음
        • University of Pennsylvania - Abramson Cancer Center
        • 수석 연구원:
          • Stefan Barta
        • 연락하다:
    • Texas
      • Houston, Texas, 미국, 77030
        • 모병
        • The University of Texas - MD Anderson Cancer Center
        • 수석 연구원:
          • Ranjit Nair
        • 연락하다:
      • Madrid, 스페인, 28027
        • 아직 모집하지 않음
        • Clinica Universidad de Navarra - Hematología y Hemoterapia
        • 연락하다:
        • 수석 연구원:
          • Migue Canales Albendea
    • Barcelona
      • Badalona, Barcelona, 스페인, 8036
        • 아직 모집하지 않음
        • Hospital Clinic De Barcelona - Hematología
        • 수석 연구원:
          • Pablo Mozas
        • 연락하다:
      • L'Hospitalet de Llobregat, Barcelona, 스페인, 8907
        • 아직 모집하지 않음
        • Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
        • 수석 연구원:
          • Eva Domingo Domenech
        • 연락하다:
    • Navarre
      • Pamplona, Navarre, 스페인, 31008
        • 아직 모집하지 않음
        • Clinica Universidad de Navarra - Hematología
        • 연락하다:
        • 수석 연구원:
          • Miguel Canales Albendea
      • Bergamo, 이탈리아, 24127
        • 아직 모집하지 않음
        • Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
        • 수석 연구원:
          • Giuseppe Gritti
        • 연락하다:
      • Bologna, 이탈리아, 40138
        • 아직 모집하지 않음
        • Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
        • 연락하다:
        • 수석 연구원:
          • Luigi Zinzani Pier
      • Torino, 이탈리아, 10126
        • 아직 모집하지 않음
        • AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
        • 연락하다:
        • 수석 연구원:
          • Federica Cavallo
    • Torino
      • Candiolo, Torino, 이탈리아, 10060
        • 아직 모집하지 않음
        • Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
        • 수석 연구원:
          • Umberto Vitolo
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
  • PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
  • Availability of tumor tissue (current or archival) is required.
  • Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
  • ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
  • Body weight 40 kg to ≤ 200 kg
  • Life expectancy ≥3 months.
  • Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
  • Restrictions on gamete donation and freezing during and after treatment.
  • Ability to provide informed consent and comply with study procedures. -

Exclusion Criteria:

  • Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
  • Pregnant or breastfeeding females, or those intending pregnancy.
  • History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
  • Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
  • Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
  • Use of other investigational drugs within 14 days or 5 half-lives before treatment.
  • Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
  • Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
  • Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
  • Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
  • Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
  • Prolonged QT/QTc interval (e.g., QTcF >480 ms).
  • Active second primary malignancies except specified non-exclusionary cases.
  • CNS involvement.
  • Any condition that may impair compliance or study completion as judged by the Investigator.
  • Known hypersensitivity to any excipients in the drug formulation.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part One (Dose Escalation)

In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design.

Intravenous infusion

실험적: Part Two (Backfill)

Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment.

Intravenous infusion

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years

Vital signs (mmHg in Systolic/Diastolic blood pressure)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years

Pulse rate (beats/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years

Respiratory Rate (breath/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years

Temperature (°Celcius)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years

ECG parameters (PR interval, QRS interval, QT interval, QTc interval)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
기간: Through study completion, an average of 1.5 years

Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD)

Through study completion, an average of 1.5 years

2차 결과 측정

결과 측정
측정값 설명
기간
Mean Blood Drug Concentration
기간: Through study completion, an average of 1.5 years

The mean drug concentration in the blood

Through study completion, an average of 1.5 years
To evaluate the immunogenicity of KK2223.
기간: Through study completion, an average of 1.5 years

Incidence of Anti drug antibodies (ADA) in blood

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
기간: Through study completion, an average of 1.5 years

% in Overall Response Rate (ORR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
기간: Through study completion, an average of 1.5 years

% in Compartment Response (if applicable)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
기간: Through study completion, an average of 1.5 years

Time unit (week/month) in Duration of Response (DOR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
기간: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
기간: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Response (TTR)

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
기간: Through study completion, an average of 1.5 years

The maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
기간: Through study completion, an average of 1.5 years

A measure of the overall drug exposure over time

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
기간: Through study completion, an average of 1.5 years

The time taken to reach the maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
기간: Through study completion, an average of 1.5 years

The time required for the drug concentration to decrease by 50%

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Clearance (CL)
기간: Through study completion, an average of 1.5 years

Rate of drug elimination from the body

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
기간: Through study completion, an average of 1.5 years

Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues

Through study completion, an average of 1.5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 9월 2일

기본 완료 (추정된)

2029년 3월 1일

연구 완료 (추정된)

2030년 9월 1일

연구 등록 날짜

최초 제출

2025년 8월 12일

QC 기준을 충족하는 최초 제출

2025년 9월 17일

처음 게시됨 (실제)

2025년 9월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 30일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 29일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2223-001

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .